Moment: The Dangerous Illusion of “Peace of Mind” From Whole-Body MRIs

Summary

---

Episode Overview

Title: Moment: The Dangerous Illusion of “Peace of Mind” From Whole-Body MRIs
Host: Dr. Rena Malik, MD
Guest: Dr. Matthew Davenport
Release Date: January 28, 2026

Theme:
This episode critically examines the trend of elective whole-body MRI screening in people without symptoms (“general risk” populations). Dr. Rena Malik and Dr. Matthew Davenport engage in a candid discussion about why such screening—often marketed as a way to achieve “peace of mind”—can paradoxically lead to substantial harm through over-detection, anxiety, and unnecessary procedures. Dr. Davenport distills complex medical evidence and examples to dispel common myths, highlight cognitive traps, and advocate for evidence-driven screening meant to genuinely improve outcomes, not just feed illusions of safety.

---

Key Discussion Points & Insights

1. Use of Contrast in Whole-Body MRIs

• [00:00] Contrast is generally avoided in commercial whole-body MRIs for healthy customers due to practicality and the rare but real risks involved (IV placement, contrast side effects).
• For patients with high-risk cancer syndromes, contrast is used because the benefit outweighs rare harms: “In that case, the benefits of giving contrast outweigh the harms because that pretest probability of disease is so high.” – Dr. Davenport [00:13]
• For average-risk people, companies don’t use contrast—mainly to avoid hassle and harm—and consequently sacrifice diagnostic accuracy.

2. The Intuitive (but Risky) Logic of “I Just Want to Know”

• [00:59] Dr. Malik voices a common patient sentiment: “I want to know what’s there, I’m not worried about the harm... if I think it’s low risk, I won’t act on it.”

• Dr. Davenport’s response: this logic makes sense for patients and even many doctors, but in reality, once something “suspicious” appears in a scan, it’s psychologically and medically difficult to ignore, leading to cascades of action—even if unnecessary.

  “Once you identify something, it’s very hard to unsee that thing.”
  — Dr. Matthew Davenport [01:34]

3. The Case Study of Thyroid Cancer Overdiagnosis

• [01:30–06:00]

  • Large-scale introduction of thyroid cancer screening in the US and South Korea dramatically increased cancer detection rates (3–11x) and thousands underwent surgery for these findings—often with complications.
  • Crucially: Despite more detected and treated cancers, the death rate from thyroid cancer did not change.
  • The described phenomenon: “an epidemic of thyroid cancer screening.”

    “What we end up doing actually is we caused a ton of unnecessary surgeries.”
    — Dr. Davenport [04:29]

• Illustration of how good intentions, incentives, and patient emotions lead all parties (patients, doctors, payers) to treat trivial findings, mistaking detection for benefit—when in the long run, it’s harm.

• “Once you look and you find it’s very hard to unwind that... You may have a cancer, [so] patients are going to be pretty motivated to do something about that.” — Dr. Davenport [05:10]

• Distinction between types of cancer and which are amenable to screening.

4. Which Cancers Should Be Screened For?

• [06:15–07:55]

  • Cancers fall into three “crude” buckets: indolent (unlikely to harm), aggressive (develop and become dangerous quickly), and intermediate (progression detectable with screening).

  • Effective screening aims for the intermediates, where intervention genuinely improves outcomes.

    “The really aggressive cancers... are not really well suited to screening... the indolent cancers... you end up driving a lot of treatments... that creates an illusion of benefit, but it’s not actually helping.”
    — Dr. Davenport [06:59]

• Example: 20-year randomized prostate cancer screening trial—a 13% decrease in prostate-cancer-related mortality (a real benefit in the right population), but also a 30% increase in cancer detections—a lot of which is overdiagnosis.

  • The key: focus screening on populations where benefit exceeds harm.

    “The population has to have sufficient risk to justify doing it, otherwise the harm starts to outweigh the benefits and you end up hurting patient populations.”
    — Dr. Davenport [07:45]

5. The Cascade of Care: A Real-World Horror Story

• [08:35–12:00]

  • Dr. Davenport relays a patient’s ordeal (with her permission), published in The New England Journal of Medicine:
    1. Woman has MRI for shoulder pain, incidentally finds lung nodule.
    2. Multiple follow-up scans (CT chest, PET scan, pelvic MRI) discover more “possible” findings.
    3. Leads to hysterectomy (removal of uterus) for a mass found to be benign fibroids.
    4. Post-surgical complications, three colonoscopies, and ongoing suggestions for further workup—despite initial health.
    5. In the end, lung nodules were “meaningless”; all findings benign; but patient suffered invasive surgery and a year of fear.

  “Once you get on the train, you can’t get off the train... The person’s living their life... but for about a year... they were terrified they were going to die.”
  — Dr. Davenport [12:07]

  “[This] is the risk, unfortunately, of doing sensitive imaging tests in low risk patient populations.”
  — Dr. Davenport [11:18]

6. Common Biases in Screening: Why Numbers Lie

• [12:15–14:13]

  • Lead time bias: Early detection appears to extend lives, even if it doesn’t change when death would have occurred.
  • Length bias: Indolent (slow-growing) conditions are more likely to be picked up than dangerous fast-growing diseases, so screening tends to over-detect the harmless (not the deadly).
  • Over-diagnosis bias: The more you look, the more trivial or irrelevant abnormalities you find.

  “This length bias helps explain why a lot of the things we find when we’re over detecting end up being those indolent or low risk diseases... we have flipped or inverted the ratio of important disease.”
  — Dr. Davenport [13:47]

---

Notable Quotes & Memorable Moments

• “Once you identify something, it’s very hard to unsee that thing.”
  — Dr. Matthew Davenport [01:34]

• “All the incentives and all the ideas are along the lines of ‘we’re doing a good thing’... and only in retrospect you say, actually we didn’t help. What we ended up doing was we caused a ton of unnecessary surgeries.”
  — Dr. Matthew Davenport [04:18]

• “Once you get on the train, you can’t get off the train.”
  — Dr. Matthew Davenport [12:07], describing the “cascade of care”

• “This is the risk, unfortunately, of doing sensitive imaging tests in low risk patient populations, because you’re going to overwhelmingly detect these indolent or unimportant findings.”
  — Dr. Matthew Davenport [11:18]

• “This length bias helps explain why a lot of the things we find when we’re over detecting end up being those indolent or low risk diseases...”
  — Dr. Matthew Davenport [13:47]

---

Timestamps for Important Segments

• 00:00 – The difference between using contrast in whole-body MRIs: high-risk vs general-risk populations
• 01:00 – The intuitive patient logic and its dangers
• 01:30–06:00 – Thyroid cancer overdiagnosis: international lessons
• 06:15 – Which cancers are worth screening for
• 08:35 – Real-life cascade-of-care patient story
• 12:03–14:13 – Screening biases: lead time, length, and over-diagnosis

---

Summary & Takeaway

Commercial whole-body MRI for well people creates a dangerous illusion of safety. As Dr. Davenport passionately, and with evidence, explains: in low-risk people, these scans more often lead to harm (anxiety, unnecessary interventions, and suffering) than saved lives. True health optimization and cancer screening should be guided by robust data on whom it helps, not by a false promise of “peace of mind.”

For listeners:

• Consider not just the possibility of “finding something,” but whether finding it will actually help.
• Trust well-validated, targeted screening plans over the allure of catch-all tests.

Check out the full episode for more from Dr. Davenport and Dr. Malik’s insightful discussion.

Transcript

[A]

The whole body MRIs are not using any contrast material. Would they be any different, like in terms of harm or benefit if they were using contrast?

[B]

Yeah, good question. For patient populations that have an indication for whole body mri. These cancer syndromes I mentioned to you before, they actually do use contrast material and they use it because it allows you to detect and characterize things that are inside your body. In that case, the benefits of giving contrast outweigh the harms because that pre test probability of disease is so high in an average or general risk population. These companies are electing not to use contrast material because it raises a lot of considerations for them as a company, and I don't want to speak on behalf of them, but it involves putting an IV catheter in. It involves being administered a contrast material that might have direct potential harm to you. It's rare for that to occur. But you're sort of trading off diagnostic accuracy for harms from the contrast.

[A]

You mentioned substantial harm and you've seen some instances where this could lead to substantial harm. Because I'm sitting here as say an individual and I'm thinking, well, I'm okay, I want to know what's there. I don't care what the potential harm is because I can make the decision if I want to do something invasive or not. Once I know that information is there and if I think it's something that has a low risk and my doctor tells me yes, it's there, but it's low risk, I'm not going to then go do something about it. So I'm not worried about the harm. But then what if they find something that's really concerning and then I'm willing to take that risk.

[B]

Right? Yeah. And that, that, by the way, that logic is very intuitive and if I was a layperson, I probably think the exact same way. Frankly, most healthcare providers think that way too. I know a lot of healthcare providers that have that same logic. Here's the challenge is that once you identify something, it's very hard to unsee that thing. And I'll give you a specific example. In patients who are over the age of 50, it's very common for you to have a thyroid nodule, which means your thyroid gland, which is in your neck. It's very common for you to have a nodule that grows in your thyroid gland. It's also very common for thyroid nodules to have small cancers in them. And this logic, well, if you're an older patient who's maybe over the age of 50, thyroid nodules are common cancer in Thyroid nodules is common, therefore we should go look for it. In fact, this is exactly what was done in the United States and also more formally in South Korea. What we saw when this happened, this well intentioned effort to go find common cancer, you ended up seeing a dramatic increase in the incidence of thyroid cancer in both countries. In the US it was by about 3 or 4x and in South Korea it was like by 9 to 11x. So a dramatic increase in the detection of cancer. Now we would think that's great, we've identified early stage cancer, now we can treat it. And in both of those examples, that's exactly what happened, is there was a well intentioned, thoughtful effort. Well, we found the cancer, let's go treat it. And lots of people had their thyroid glands taken out. Tens of thousands of patients, lots of people had injury to the nerves in their neck which caused problems. They lost these little glands called the hypoparathyroid glands that are in their neck and caused some hormonal complications. And many of these patients ended up on lifelong hormone supplementation. And only when you looked back in retrospect and said, let's see how we did, let's see if we've helped the population, we detected all these thousands of additional cancers. How did we do? And what you saw is that the mortality from thyroid cancer did not change. So you end up with this tidal wave of detection of cancers. And everyone in the process thinks we're doing a good thing. The patient rationally thinks, I've detected early cancer and they've probably told all their friends and relatives, my life was saved. The doctor, well intentioned, says, we've detected a cancer early, we've saved this person's life. The payers, whether it's the government agency or a third party payer, is saying, well, this is a reasonable thing to do, cancer should be treated. And so all the incentives and all the ideas are along the lines of we're doing a good thing. And only in retrospect you say, actually we didn't help. What we ended up doing actually was we caused a ton of unnecessary surgeries. And this was described in the New England Journal of Medicine articles, a series of them in the mid 2010s, and they described it as a, quote, epidemic of thyroid cancer screening. The steps that were taken are, please stop, please stop looking. Because once you look and you find it's very hard to unwind that we see this in a lot of other situations, in urology, for example, in small renal masses, in urology, for example, in low Risk prostate cancer. There's interest in pursuing things like active surveillance and sort of holding back and not doing it, but gosh, it's hard to do. And the average patient, when they're told, you know, you may have a cancer, they're going to be pretty motivated to do something about that. And it comes back to what kind of cancer are we detecting? That's the crux of this, what kind of cancer? So if I have a very low pretest probability of aggressive disease, which is the average risk population, if I have a low pretest probability disease, the kinds of cancers I'm overwhelmingly going to find are those that are indolent. So you can think of cancers in kind of. This is very crude and I apologize, but kind of three basic buckets. You've got your indolent cancers that are very unlikely to actually hurt you, but they are common and dwell in your body. You have some that are aggressive which could go from development to metastatic disease really fast, like maybe in six months. And you have those which are kind of in the middle where they have a stepwise progression of going from something indolent to something a little bit more sinister to something that's bad. If you think about those three kinds of cancers, the ones that you want to target for screening are the ones that are in the middle that this stepwise progression, and we see this in patients who have rather randomized trials which recommends screening for things like colorectal cancer or prostate cancer or breast cancer, with certain kinds of cancers are being targeted, kind of an intermediate growth phase. The really aggressive cancers, the ones that kind of develop and go from zero to horrible real fast, they're not really well suited to screening because the odds that you randomly happen to image the person within maybe a one to two month window that you have before you can even do something, pour the cats out of the bag, it's just statistically unlikely. And the indolent cancers, if you end up detecting a lot of those, you end up driving a lot of treatments, a lot of biopsies and all the complications from surgeries and stuff that creates an illusion of benefit, but it's not actually helping. And in fact, this over diagnosis problem is prevalent actually in prostate cancer. And it's one of the reasons why it's generated so much kind of feelings and complication around what's the right kind of prostate cancer screening to do. A recent study just came out a couple weeks ago, a very famous study was conducted over a 20 year period, enrolled like 160,000 men randomized to get PSA screening or not. Now, obviously in all these trials, a little bit of cross contamination where people kind of choose to do something they're not supposed to do, according to the trial. But they showed essentially by doing prostate cancer screening, it was confirmed to result in a 13% decrease in prostate cancer related mortality. Which is great. That's amazing. That's amazing. And that says to me, we have randomized trial evidence saying this is the right thing to do for this patient population that's of a particular risk. And what they also found in that study, and what they also highlighted is that patients who opted into screening had a 30% increased detection of cancer. And a lot of that cancer that was being detected was over diagnosis. Some of it was appropriate, and you're getting some treatment benefit of that survival benefit, which is that mortality benefit, which is exactly what you want. Some of what's being detected, a lot of what's being detected is over diagnosis and being smart with the screening strategy and trying to angle it in such a way that it targets the higher risk ones and minimize the low risk ones. It's a combination of doing two things. One is being smart, like you said, and two is targeting the right population. The population has to have sufficient risk to justify doing it, otherwise the harm starts to outweigh the benefits and you end up hurting patient populations. It's the same reason we don't do, for example, colonoscopy based screening in 20 year olds. Because the harms outweigh the benefits.

[A]

Yeah, yeah, it is scary. So think about it. You find a nodule in your thyroid, you have a surgery, you injure your vocal, your nerves in your neck, and you have chronic pain for the rest of your life for something that you didn't need. Right, That's, I mean, that's the one that we can take from your example. But many of these things can happen. You can have very unfortunate circumstances, even from biopsies, even from endoscopies, these sort of tests that you do to diagnose an incidental finding on an mri.

[B]

That's right. And I would say this is really common. And we end up dwelling a lot in anecdotes with this topic because we lack randomized trial data around it. So, you know, one side says there was an anecdote where someone found a finding and my life was saved. The other side you give an anecdote of, you know. Yes, but here's all the terrible harms that could happen. I can give you, I can give you one example of this. This is a very dramatic example. And I Have permission to share this from the person involved. It actually was published in a New England Journal of Medicine evidence article. So essentially, the person goes in because they have some shoulder pain, and their plan is to get their shoulder injected because their shoulder hurts. They get an MRI to evaluate the shoulder. And on the shoulder mri, they found a lung nodule. They said, oh, no, found a lung nodule. What are we going to do about that? So this is a classic example of an incidental finding. I mentioned before. About 20 to 40% of all these advanced imaging studies have insulin findings. This is a classic example of one. This individual is maybe in her late 40s, early 50s, has no particular risk of any lung disease. They're not a smoker, but nonetheless, they found a nodule. They said, well, we're not sure what it is. You have a low pretest probability of disease. But we have now generated uncertainty. We found something. Why don't we do a chest CT and figure out if there's other nodules? So they did, and they found actually lots of nodules all over the chest. There were a whole bunch of them. And the person was obviously terrified. And we didn't know what it was. And they thought, well, maybe it could be metastatic disease from some unknown cancer, maybe it could be some bad infection. We're not sure what it is. Why don't we do a PET scan? We talked about that earlier. And so she's gotten the radiation from the ct. Now she's going to get the radiation from the PET ct. And it turns out that none of the lung nodules showed any significant uptake. But what they did find on the PET scan was they found something in the pelvis, and there was a little bit of uptake around the. They call it the Adnexa, kind of like where the ovary is. And the PET scan said, you know, the lung nodules are not showing any uptake, but maybe this problem is down in the ovary. Why don't we go take a look at that? So they ended up with a pelvis mri. So, kind of counting the studies here, we've got a CT scan, we have a PET scan, we have an MRI of the pelvis. MRI of the pelvis says the ovary is actually normal. We think maybe that was just some artifact from the ureter coming by. But there's some findings in the uterus, and there's a bunch of masses in the uterus. They're probably all fibroids, which are benign masses, but one of them looks a little funny. And what if those lung Nodules are actually something funny from this uterine mass. And what was recommended was to remove the uterus. This person now has surgery to take out the uterus for this lung nodules, which they were all benign masses. And I'm going to cut to the chase. But after this hysterectomy was done, the person developed a wound infection, an allergic reaction to some of the antibiotics that they were taking. They've had, I think, three colonoscopies because they still know what the heck the lung nodules are. And they were being offered a biopsy for the lung nodules. And the person said, stop, please stop. I'm being tortured. And this is what happens as you get on they call. This is a famous description of this called a cascade of care, and it's well described by primary care doctors where one thing begets another thing begets another thing and you end up in this vortex and you can't get yourself out again. And this is the risk, unfortunately, of doing sensitive imaging tests in low risk patient populations, because you're going to overwhelmingly detect these indolent or unimportant findings. And by the way, the, the conclusion of the story is these lung nodules have no meaning in her life and she's completely fine.

[A]

And was her uterine mass something.

[B]

They were benign, they were fibroids benign. So it was all just a rabbit chase. It was all pointless. But once you get on the train, you can't get off the train. The person's living their life. They're a totally functional, happy person. But for about a year of their life, they were terrified they were going to die of metastatic disease. And they had an unnecessary surgery and complications from surgery. And that is the problem when we do this, if we have time. I'd like to just describe one thing. We have screening tests. Screening tests are affected by common biases. You can think about whole body MRI as a screen essentially of your body. And some of these biases of screening which are very well known are length bias, lead time bias, and over diagnosis bias. So lead time bias, what that basically means is let's say that you have cancer that's detected and you live for three more years. Your apparent survival was three years with that cancer. Now, let's say we detected that cancer actually two years earlier by some imaging test. Well, now I've got two years from me knowing about it, and then the symptoms develop and I got three. So two plus three is five in that patient. Even if I do nothing, even if I don't treat the disease, even if I'VE given them no therapy, their apparent survival is longer. And this is a common bias of screening, a more insidious bias which I think is very common with whole body MRI and other things like it is something called length bias. It goes like this. Let's imagine you have two types of bad things. One is really indolent and unlikely to hurt you over a 20 year time frame. And one is something that's very aggressive and is going to go from like just starting to going to kill you within one year. And let's say they're equally prevalent in the population. And I randomly sample the population, just randomly choose, you know, I'm going to image you on this year, this year. The thing that I'm going to overwhelmingly detect are the things that are going to be in your body for 20 years as opposed to things going to be in your body for six months or 12 months because I'm randomly sampling the population. This length bias helps explain why a lot of the things we find when we're over detecting end up being those indolent or low risk disease because we have flipped or inverted the ratio of important disease.

[A]

And if you like this clip with Dr. Matthew Davenport, make sure to check out the full episode right here.